Save Product
Product Details
Synonyms
ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1
Source
Rat Her2 Protein, Tag Free (HE2-R5213) is expressed from human 293 cells (HEK293). It contains AA Thr 26 - Thr 656 (Accession # AAH61863.1).
Predicted N-terminus: Thr 26
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries no "tag".
The protein has a calculated MW of 69.7 kDa. The protein migrates as 70 kDa and 80-95 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Rat Her2 Protein, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Rat Her2 Protein, Tag Free (Cat. No. HE2-R5213) is more than 90% and the molecular weight of this protein is around 75-105 kDa verified by SEC-MALS.
Report
Customer Reviews Writing Reviews
Background
Aberrant amplification or overexpression of the HER2/neu proto-oncogene is a key oncogenic driver. In breast cancer, approximately 25-30% of patients exhibit HER2 overexpression, leading to a more aggressive disease phenotype with faster growth, increased metastasis, and often reduced chemotherapy sensitivity. This correlates with poorer prognosis and makes HER2 a critical prognostic, predictive biomarker, and a major therapeutic target.
Recent Advances
Drug Development Progress- English Name：
Receptor protein-tyrosine kinase erbB-2
- Category：
- Approved Drugs：
47 Details
- Drugs in Clinical Trials：
238 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
